» Articles » PMID: 36455762

Optimizing Quantification of MK6240 Tau PET in Unimpaired Older Adults

Abstract

Accurate measurement of Alzheimer's disease (AD) pathology in older adults without significant clinical impairment is critical to assessing intervention strategies aimed at slowing AD-related cognitive decline. The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (POINTER) is a 2-year randomized controlled trial to evaluate the effect of multicomponent risk reduction strategies in older adults (60-79 years) who are cognitively unimpaired but at increased risk for cognitive decline/dementia due to factors such as cardiovascular disease and family history. The POINTER Imaging ancillary study is collecting tau-PET ([F]MK6240), beta-amyloid (Aβ)-PET ([F]florbetaben [FBB]) and MRI data to evaluate neuroimaging biomarkers of AD and cerebrovascular pathophysiology in this at-risk sample. Here 481 participants (70.0±5.0; 66% F) with baseline MK6240, FBB and structural MRI scans were included. PET scans were coregistered to the structural MRI which was used to create FreeSurfer-defined reference regions and target regions of interest (ROIs). We also created off-target signal (OTS) ROIs to examine the magnitude and distribution of MK6240 OTS across the brain as well as relationships between OTS and age, sex, and race. OTS was unimodally distributed, highly correlated across OTS ROIs and related to younger age and sex but not race. Aiming to identify an optimal processing approach for MK6240 that would reduce the influence of OTS, we compared our previously validated MRI-guided standard PET processing and 6 alternative approaches. The alternate approaches included combinations of reference region erosion and meningeal OTS masking before spatial smoothing as well as partial volume correction. To compare processing approaches we examined relationships between target ROIs (entorhinal cortex (ERC), hippocampus or a temporal meta-ROI (MetaROI)) SUVR and age, sex, race, Aβ and a general cognitive status measure, the Modified Telephone Interview for Cognitive Status (TICSm). Overall, the processing approaches performed similarly, and none showed a meaningful improvement over standard processing. Across processing approaches we observed previously reported relationships with MK6240 target ROIs including positive associations with age, an Aβ+> Aβ- effect and negative associations with cognition. In sum, we demonstrated that different methods for minimizing effects of OTS, which is highly correlated across the brain within subject, produced no substantive change in our performance metrics. This is likely because OTS contaminates both reference and target regions and this contamination largely cancels out in SUVR data. Caution should be used when efforts to reduce OTS focus on target or reference regions in isolation as this may exacerbate OTS contamination in SUVR data.

Citing Articles

[F]MK-6240 Radioligand Delivery Indices as Surrogates of Cerebral Perfusion: Bias and Correlation Against [O]Water.

Fu J, Juttukonda M, Garimella A, Salvatore A, Lois C, Ranasinghe A J Nucl Med. 2025; 66(3):410-417.

PMID: 39947916 PMC: 11876731. DOI: 10.2967/jnumed.124.268701.


Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.

Matsuda H, Hanyu H, Kaneko C, Ogura M, Yamao T Ann Nucl Med. 2025; .

PMID: 39873881 DOI: 10.1007/s12149-025-02018-7.


In Vivo Head-to-Head Comparison of [F]GTP1 with [F]MK-6240 and [F]PI-2620 in Alzheimer Disease.

Olafson E, Tonietto M, Klein G, Teng E, Stephens A, Russell D J Nucl Med. 2025; 66(2):277-285.

PMID: 39746756 PMC: 11800736. DOI: 10.2967/jnumed.124.268623.


Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification.

Landau S, Harrison T, Baker S, Boswell M, Lee J, Taggett J Alzheimers Dement. 2024; 21(1):e14378.

PMID: 39559932 PMC: 11772732. DOI: 10.1002/alz.14378.


Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.

Matsuda H, Yamao T Fukushima J Med Sci. 2023; 69(2):85-93.

PMID: 37302841 PMC: 10480511. DOI: 10.5387/fms.2023-08.


References
1.
Phillips J, Das S, McMillan C, Irwin D, Roll E, Da Re F . Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp. 2017; 39(2):691-708. PMC: 5764792. DOI: 10.1002/hbm.23874. View

2.
Buckley R, ODonnell A, McGrath E, Jacobs H, Lois C, Satizabal C . Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. Ann Neurol. 2022; 92(1):11-22. PMC: 9233144. DOI: 10.1002/ana.26382. View

3.
Royse S, Minhas D, Lopresti B, Murphy A, Ward T, Koeppe R . Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021; 13(1):99. PMC: 8111744. DOI: 10.1186/s13195-021-00836-1. View

4.
Bejanin A, Schonhaut D, La Joie R, Kramer J, Baker S, Sosa N . Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. Brain. 2017; 140(12):3286-3300. PMC: 5841139. DOI: 10.1093/brain/awx243. View

5.
Scholl M, Maass A, Mattsson N, Ashton N, Blennow K, Zetterberg H . Biomarkers for tau pathology. Mol Cell Neurosci. 2018; 97:18-33. PMC: 6584358. DOI: 10.1016/j.mcn.2018.12.001. View